What You Ought to Know:
– OneCell Diagnostics, a genomics-based precision oncology firm, introduced immediately that it has raised $16M in an oversubscribed Collection A funding spherical led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
– The funding can be used to advance its imaginative and prescient of democratizing precision oncology by most cancers diagnostic testing that’s extra accessible, actionable, and inexpensive. Celesta Capital Founding Managing Companion Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will be part of the OneCell board of administrators.
OneCell Diagnostics: Revolutionizing Precision Oncology with Genomic Improvements
OneCell Diagnostics is a pioneering precision oncology firm specializing in genomics-based options to reinforce most cancers administration. Its proprietary platform combines next-generation sequencing with superior bioinformatics, synthetic intelligence (AI), machine studying (ML), and multi-omics biomarker evaluation to ship cutting-edge most cancers diagnostics.
- Liquid Biopsy Expertise:
OneCell’s groundbreaking True-Single-Cell-Multi-omics platform drives its precision oncology diagnostics. The expertise integrates Circulating Tumor Cell (CTC) DNA, CTC RNA, and cell floor protein testing from a single blood draw, representing a big development over typical liquid biopsy strategies. Purposes embody:- Most cancers screening.
- Monitoring remedy response.
- Detecting illness development and recurrence.
- Flagship Product:
With Collection A funding, OneCell is launching its next-generation liquid biopsy check, OncoIndx Ikon, within the U.S. market. This check detects and analyzes CTCs, offering actionable biomarkers that improve prognosis and remedy methods for most cancers sufferers. - International Influence and Attain:
Working from Silicon Valley and India, OneCell has already examined almost 10,000 sufferers in India, showcasing the scalability, security, and cost-effectiveness of its expertise in medical and laboratory settings. - Collaborations and Partnerships:
Strategic partnerships with main establishments like Harvard Medical College and Stanford College bolster OneCell’s technological developments and medical functions. - Addressing a International Problem:
In response to the World Well being Group, most cancers impacts 20 million new sufferers yearly, with 53.5 million dwelling inside 5 years of prognosis. As most cancers is pushed by fixed molecular-level modifications, biomarker testing is important. Over half of worldwide oncology medical trials now combine biomarker testing to refine remedy selections and monitor illness response throughout remedy.
By leveraging cutting-edge genomics and multi-omics applied sciences, OneCell Diagnostics is remodeling the panorama of most cancers diagnostics and precision oncology worldwide.
“We see a future the place everybody has entry to high-quality, life-saving most cancers testing and this funding is a robust validation of our imaginative and prescient,” stated Mohan Uttarwar, CEO and Co-founder at OneCell Diagnostics. “By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we now have the chance to interrupt new floor in delivering correct, personalised most cancers care worldwide.”
